Clinical trial · Interventional
Role of Perfluorobutane in Lesion Detection, Targeting and Response Assessment for Ablation of HCC
Role of Kupffer Phase Specific Ultrasound Contrast Agent (Perfluorobutane) in Lesion Detection, Targeting and Response Assessment for Ablation Therapy (Radiofrequency/ Microwave Ablation) of Hepatocellular Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Primary liver cancers are the sixth most common malignancies worldwide, with hepatocellular carcinoma (HCC) accounting for approximately 80% of them. The Barcelona Clinic Liver Cancer (BCLC) classification is widely used in the management of HCC. At the time of diagnosis, fewer than 30% of the patients qualify for resection or transplant due to the large size or multiplicity of the lesions, background chronic liver disease, and other comorbidities. However, the recent spread of surveillance has led to early detection of hepatocellular carcinoma (HCC), and the chance of receiving local treatment has increased. There are several options to treat small HCCs, including surgical resection, chemical ablation, transplantation, and percutaneous ablation (RFA/MWA). Today, percutaneous ablation plays a key role in the treatment of early-stage HCC because it is less invasive than surgical resection and has a good efficacy. However, targeting of lesions under USG alone may be misleading as there may be an enhancing component which is not seen on plain ultrasound. To overcome this problem contrast enhanced ultrasound may be used intra-procedurally, however conventional ultrasound contrast agents show washout by 5 minutes from the system. In this study, the investigators prospectively analyze patients undergoing ablation with the help of precise needle placement using a Kupffer phase ultrasound contrast agent (perfluorobutane) and their post procedure response assessment.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Microwave Ablation | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Perfluorobutane | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Patients undergoing ablation for HCC
- description
- Pre-procedure CEUS will be performed on patients undergoing ablation followed by targeting of lesions for precise needle placement in the Kupffer phase. 2 hours post procedure USG with contrast will also be done for response assessment
- interventionNames
- Drug: Perfluorobutane
Primary outcomes (1)
- measure
- Comparison of treatment response two hours post procedure with Perfluorobutane with routine CECT/CEMRI done at 1 month post procedure using modified RECIST criteria for HCC.
- timeFrame
- upto 6 months
- description
- Post procedure CEUS will be done which will be compared with 1 month CECT/CEMRI to compare treatment response of ablation
Secondary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Adult s (18 80 years) with HCC and who refused surgical resection 2. Tumour number not more than five and the largest tumour size not larger than 5.0 cm; 3. Ill defined lesions which are not easily detected on grey scale USG for lesion targeting. 4. Liver function status at Child Pugh class A or B; 5. East Coast Oncology Group (ECOG) performance status value 0 or 1; 6. No severe coagulopathy (e.g. platelets ≥50,000/ prothrombin time ratio ≥ 50%). 7. Available medical records and/or imaging studies. Exclusion Criteria: 1. Presence of vascular invasion and extrahepatic metastases at pre procedure imaging study; 2. Ongoing anticoagulant treatment that cannot be stopped; 3. Combined TACE and ablation for a larger lesion
References
Publications (1)
- DERIVEDMukund A, Bansal A, Patidar Y, Thapar S, Sharma MK, Sarin SK. Role of contrast-enhanced ultrasound with Perfluorobutane in lesion detection, guidance for microwave ablation, and response assessment of hepatocellular carcinoma. Abdom Radiol (NY). 2022 Oct;47(10):3459-3467. doi: 10.1007/s00261-022-03609-y. Epub 2022 Jul 16. PMID 35842563